The findings reveal that vaccine efficacy against clinical and severe malaria was better in children than in young infants, but waned over time in both groups. However, protection was prolonged by a booster dose, increasing the average number of cases prevented in both children and young infants.
Brian Greenwood, corresponding author and Professor of Clinical Tropical Medicine at London School of Hygiene & Tropical Medicine in the UK explains, "Despite the falling efficacy over time, there is still a clear benefit from RTS,S/AS01. An average 1363 cases of clinical malaria were prevented over 4 years of follow-up for every 1000 children vaccinated, and 1774 cases in those who also received a booster shot. Over 3 years of follow-up, an average 558 cases were averted for every 1000 infants vaccinated, and 983 cases in those also given a booster dose."
"Given that there were an estimated 198 million malaria cases in 2013, this level of efficacy potentially translates into millions of cases of malaria in children being prevented."
The RTS,S/AS01 vaccine was developed for use in sub-Saharan Africa where malaria still kills around 1300 children every day. There is currently no licensed vaccine against malaria anywhere in the world.
The phase 3 randomised trial enrolled 15459 young infants (aged 6 to 12 weeks at first vaccination) and children (5 to 17 months at first vaccination) from 11 sites across seven sub-Saharan African countries (Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and United Republic of Tanzania) with varying levels of malaria transmission. In 2014, initial phase 3 results at 18 months showed vaccine efficacy of about 46% against clinical malaria in children and around 27% among young infants .
In this study, members of the RTS,S Clinical Trials Partnership followed up the infants and children for a further 20 to 30 months, respectively, and assessed the impact of a fourth booster dose. Participants were each vaccinated three times with RTS,S/AS01 with or without a booster dose 18 months later, or given four doses of a comparator vaccine (control group).
In children who received 3 doses of RTS,S/AS01 plus a booster, the number of clinical episodes of malaria at 4 years was reduced by just over a third (36%). This is a drop in efficacy from the 50% protection against malaria seen in the first year.
Importantly, without a booster dose, significant efficacy against severe malaria was not shown in this age group. However, in children given a booster dose, overall protective efficacy against severe malaria was 32%, and 35% against malaria-associated hospitalisations.
In infants who received 3 doses of RTS,S/AS01 plus a booster, the vaccine reduced the risk of clinical episodes of malaria by 26% over 3 years follow-up. There was no significant protection against severe disease in infants.
Meningitis occurred more frequently in children given RTS,S/AS01 (11 children in the group who received the booster dose and 10 in those who did not) than in those given the control vaccine (1 child). RTS,S/AS02 produced more adverse reactions than the control vaccines. Convulsions following vaccination, although uncommon, occurred more frequently in children who received RTS,S/AS01 than in controls. The incidence of other serious adverse events was similar in all groups of participants.
According to Professor Greenwood, "The European Medicines Agency (EMA) will assess the quality, safety, and efficacy of the vaccine based on these final data. If the EMA gives a favorable opinion, WHO could recommend the use of RTS,S/AS01 as early as October this year. If licensed, RTS,S/AS01 would be the first licensed human vaccine against a parasitic disease."
Writing in a linked Comment, Vasee Moorthy and Jean Marie Okwo-Bele, from the Department of Immunization, Vaccines and Biologicals at WHO in Geneva, Switzerland say, "The donor community would need to coordinate any financing for the RTS,S/AS01 vaccine carefully, should it reach that stage. In particular, funding must not be redirected away from meeting adequate access to artemisinin-combination treatments, rapid diagnostic tests, longlasting insecticidal nets, and other malaria control measures already in place in certain settings."
This study was funded by GlaxoSmithKline Biologicals SA and the PATH Malaria Vaccine Initiative.
 media/world_malaria_report_2014/en/" href="media/world_malaria_report_2014/en/">http://www.who.int/malaria/media/world_malaria_report_2014/en/" href="http://www.who.int/malaria/media/world_malaria_report_2014/en/" _fcksavedurl="http://www.who.int/malaria/media/world_malaria_report_2014/en/">http://www.who.int/malaria/media/world_malaria_report_2014/en/">http://www.who.int/malaria/media/world_malaria_report_2014/en/">http://www.who.int/malaria/media/world_malaria_report_2014/en/
 Vaccine efficacy is the reduction in the incidence of a disease (the number of new cases that occur in a population in a given period) among trial participants who receive the vaccine compared to the incidence among participants who do not receive the vaccine.
Welcome to SUV System Ltd!
SUV System Ltd is ISO 90012008 Certified electronics distributor with 10 years of experiences.
We have built up long term business relationship with about many companies which are stockers and authorized agents. we have a steady and reliable supply to meet customer's demands to the greatest extent .Confidently, we are able to lower your cost and support your business with our years of professional service.
SUV System Ltd is Electronic Components Distributor Supplies,Find Quality Electronic Components Supplies Products IC(Integrated Circuits),Connectors,Capacitor,Resistors,Diodes,Transistors,LED at Suvsystem.com. Sourcing Other Energy, Environment, Excess Inventory Products from Manufacturers and Suppliers at Suvsystem.com
SUV System Ltd insists on the managing faith ofsincereness,speciality,foresight, win-win,so we build up stable-relationship customers located all over the world, including the States, Europe, Argentina, UAE, Malaysia, Australia,and India etc
we are focus on the following fields,and hope we can help you.
AVX Resistors Resistors TOSHIBA Diodes Switching Diodes ROHM Resistors Vishay resistors NXP Transistors Ligitek LED Chip Inductors ELPIDA IC High Precision Resistors Diodes Inc Texas Instruments(TI) IC Microchip IC Renesas parts IC MURATA IC NXP Diodes Resistor Arrays Fast Recovery Diodes MAXIM IC Bipolar Transistors NEC Transistors TOSHIBA Transistors Transistors Thin Film Resistors Chip Fuses AD IC INTERSIL IC ALTERA IC components Electronic News Zener Diodes FAIRCHILD diodes Freescale Semiconductor TI IC Cypress IC YAGEO Resistors Kingbrigt LED LED part Military IC